Genetic assay is predictive of prognosis for kidney cancer
the ONA take:
Researchers in Singapore have developed a test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC). ccRCC is the most common type of kidney cancer.
Treatment options include surgery to remove the tumor and tyrosine kinase inhibitor (TKI) therapy. Prognosis for patients, however, is difficult to predict because outcomes vary. This new test identifies genetic markers of different ccRCC subtypes.
In developing this test, the researchers identified eight genes whose expression levels differed between two subtypes of the disease.
Furthermore, the expression profiles of the eight genes proved to reliably predict good or poor prognosis in patients with ccRCC who received TKI therapy as well as underwent surgery.
The researchers report that the assay could be used as a tool to improve surveillance strategies for patients with ccRCC, but clinical trials are needed to determine the assay’s value in relation to various therapies.
A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|